Literature DB >> 23322458

Cost-related medication nonadherence in older patients with rheumatoid arthritis.

Leslie R Harrold1, Becky A Briesacher, Dan Peterson, Ashley Beard, Jeanne Madden, Fang Zhang, Jerry H Gurwitz, Stephen B Soumerai.   

Abstract

OBJECTIVE: Economic access to costly medications including biologic agents can be challenging. Our objective was to examine whether patients with rheumatoid arthritis (RA) are at particular risk for cost-related medication nonadherence (CRN) and spending less on basic needs.
METHODS: We identified a nationally representative sample of older adults with RA (n = 1100) in the Medicare Current Beneficiary Survey (2004-2008) and compared them to older adults with other morbidities categorized by chronic disease count: 0 (n = 5898), 1-2 (n = 30,538), and ≥ 3 (n = 34,837). We compared annual rates of self-reported CRN (skipping or reducing medication doses or not obtaining prescriptions because of cost) as well as spending less on basic needs to afford medications and tested for differences using survey-weighted logistic regression analyses adjusted for demographic characteristics, health status, and prescription drug coverage.
RESULTS: In the RA sample, the unadjusted weighted prevalence of CRN ranged from 20.7% in 2004 to 18.4% in 2008 as compared to 18.5% and 11.9%, respectively, in patients with 3 or more non-RA conditions. In adjusted analyses, having RA was associated with a 3.5-fold increase in the risk of CRN (OR 3.52, 95% CI 2.63-4.71) and almost a 2.5-fold risk of spending less on basic needs (OR 2.41, 95% CI 1.78-3.25) as compared to those without a chronic condition.
CONCLUSION: Patients with RA experience a high prevalence of CRN and forgoing of basic needs, more than do older adults with multiple other chronic conditions. The situation did not improve during a period of policy change aimed at alleviating high drug costs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23322458      PMCID: PMC3815617          DOI: 10.3899/jrheum.120441

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  23 in total

1.  Prescription drug coverage and seniors: how well are states closing the gap?

Authors:  Dana Gelb Safran; Patricia Neuman; Cathy Schoen; Jana E Montgomery; Wenjun Li; Ira B Wilson; Michelle S Kitchman; Andrea E Bowen; William H Rogers
Journal:  Health Aff (Millwood)       Date:  2002 Jul-Dec       Impact factor: 6.301

2.  Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D.

Authors:  Jeanne M Madden; Amy J Graves; Fang Zhang; Alyce S Adams; Becky A Briesacher; Dennis Ross-Degnan; Jerry H Gurwitz; Marsha Pierre-Jacques; Dana Gelb Safran; Gerald S Adler; Stephen B Soumerai
Journal:  JAMA       Date:  2008-04-23       Impact factor: 56.272

3.  Time trends in medication use and expenditures in older patients with rheumatoid arthritis.

Authors:  Leslie R Harrold; Daniel Peterson; Ashley J Beard; Jerry H Gurwitz; Becky A Briesacher
Journal:  Am J Med       Date:  2012-06-09       Impact factor: 4.965

4.  Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis.

Authors:  Pinar Karaca-Mandic; Geoffrey F Joyce; Dana P Goldman; Marianne Laouri
Journal:  Health Serv Res       Date:  2010-10       Impact factor: 3.402

5.  Predictors of rheumatoid arthritis patient-physician communication about medication costs during visits to rheumatologists.

Authors:  Ashley J Beard; Betsy Sleath; Susan J Blalock; Mary Roth; Morris Weinberger; Gail Tudor; Betty Chewning
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-05       Impact factor: 4.794

6.  Trends in out-of-pocket medical care expenditures for Medicare-age adults with arthritis between 1998 and 2004.

Authors:  Ithai Z Lurie; Dorothy D Dunlop; Larry M Manheim
Journal:  Arthritis Rheum       Date:  2008-08

7.  Increases in Medicare prescription drug plan costs attributable to psychotropic medications.

Authors:  Kara Zivin; Ryan J McCammon; Matthew M Davis; Lakshmi K Halasyamani; Helen C Kales
Journal:  Am J Geriatr Psychiatry       Date:  2008-08       Impact factor: 4.105

8.  Cost-related medication nonadherence after implementation of Medicare Part D, 2006-2007.

Authors:  Jeanne M Madden; Amy J Graves; Dennis Ross-Degnan; Becky A Briesacher; Stephen B Soumerai
Journal:  JAMA       Date:  2009-10-28       Impact factor: 56.272

9.  Accuracy of Medicare claims data for rheumatologic diagnoses in total hip replacement recipients.

Authors:  Elena Losina; Jane Barrett; John A Baron; Jeffrey N Katz
Journal:  J Clin Epidemiol       Date:  2003-06       Impact factor: 6.437

10.  Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.

Authors:  Jennifer M Polinski; Penny E Mohr; Lorraine Johnson
Journal:  Arthritis Rheum       Date:  2009-06-15
View more
  21 in total

1.  Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.

Authors:  Jinoos Yazdany; R Adams Dudley; Randi Chen; Grace A Lin; Chien-Wen Tseng
Journal:  Arthritis Rheumatol       Date:  2015-06       Impact factor: 10.995

2.  Social Risk Factors for Medication Nonadherence: Findings from the CARDIA Study.

Authors:  Gabriela R Oates; Lucia D Juarez; Barbara Hansen; Catarina I Kiefe; James M Shikany
Journal:  Am J Health Behav       Date:  2020-03-01

3.  Predictors of patient decision to discontinue anti-rheumatic medication in patients with rheumatoid arthritis: results from the Ontario best practices research initiative.

Authors:  Vandana Ahluwalia; Emmanouil Rampakakis; Mohammad Movahedi; Angela Cesta; Xiuying Li; John S Sampalis; Claire Bombardier
Journal:  Clin Rheumatol       Date:  2017-09-06       Impact factor: 2.980

Review 4.  [Safety of antirheumatic drug treatment in the elderly].

Authors:  K Krüger; A Strangfeld; C Kneitz
Journal:  Z Rheumatol       Date:  2014-04       Impact factor: 1.372

5.  Sociodemographic Determinants of Out-of-Pocket Expenditures for Patients Using Prescription Drugs for Rheumatoid Arthritis.

Authors:  Kumar Mukherjee; Khalid M Kamal
Journal:  Am Health Drug Benefits       Date:  2017-02

6.  Medication affordability gains following Medicare Part D are eroding among elderly with multiple chronic conditions.

Authors:  Huseyin Naci; Stephen B Soumerai; Dennis Ross-Degnan; Fang Zhang; Becky A Briesacher; Jerry H Gurwitz; Jeanne M Madden
Journal:  Health Aff (Millwood)       Date:  2014-08       Impact factor: 6.301

7.  Dr. Harrold, et al reply.

Authors:  Leslie R Harrold; Jerry H Gurwitz; Becky A Briesacher
Journal:  J Rheumatol       Date:  2013-08       Impact factor: 4.666

Review 8.  Economics of non-adherence to biologic therapies in rheumatoid arthritis.

Authors:  Mary A De Vera; Jonathan Mailman; Jessica S Galo
Journal:  Curr Rheumatol Rep       Date:  2014-11       Impact factor: 4.592

9.  Utilization of Screening Mammograms in the Medicare Population Before and After the Affordable Care Act Implementation.

Authors:  Laura M Bozzi; Bruce Stuart; Eberechukwu Onukwugha; Sarah E Tom
Journal:  J Aging Health       Date:  2018-09-22

10.  Assessing disease severity in bio-naïve patients with RA on treatment with csDMARDs: insights from the Corrona Registry.

Authors:  Leslie R Harrold; Pankaj A Patel; Jenny Griffith; Heather J Litman; Hua Feng; Casey A Schlacher; Joel M Kremer
Journal:  Clin Rheumatol       Date:  2019-10-21       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.